文献速递垂体与肾上腺疾病

难治性垂体炎的临床特征与管理框架:一项队列研究

Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-11-12

该回顾性队列研究纳入100例原发性自身免疫性垂体炎(PAH)患者,将难治性PAH定义为原发糖皮质激素抵抗或减量期间复发(糖皮质激素依赖),22例(22%)符合标准。糖皮质激素依赖型难治性PAH与较低妊娠相关垂体炎患病率、较高血清催乳素水平、较高促性腺激素性性腺功能减退症患病率及较大垂体柄直径相关。免疫抑制剂或利妥昔单抗联合治疗可有效实现影像学控制,糖皮质激素相关不良事件发生率为40.9%。

要点

  • 100例PAH患者中22例(22%)符合难治性标准,包括19例糖皮质激素依赖型和3例糖皮质激素抵抗型。
  • 糖皮质激素依赖型难治性PAH与较低妊娠相关垂体炎患病率、较高催乳素水平、较高促性腺激素性性腺功能减退症患病率及较大垂体柄直径相关。
  • 免疫抑制剂或利妥昔单抗联合治疗可有效实现影像学控制,糖皮质激素相关不良事件发生率为40.9%。

核心结论

  • 本研究定义并描述了难治性PAH的临床特征,提出的结构化诊断-治疗路径为管理这一具有挑战性的疾病提供了框架。

研究设计与样本

  • 回顾性队列研究,纳入100例原发性自身免疫性垂体炎(PAH)患者;难治性PAH定义为原发糖皮质激素抵抗或减量期间复发(糖皮质激素依赖),22例符合标准。

主要发现

  • 100例垂体炎患者中22例(22%)符合难治性疾病标准,包括19例糖皮质激素依赖型和3例糖皮质激素抵抗型。
  • 与无难治组相比,糖皮质激素依赖型难治组妊娠相关垂体炎患病率更低(5.9% vs 41.7%,p=0.006),血清催乳素水平更高(中位数30.2 ng/mL vs 17.8 ng/mL,p=0.021),促性腺激素性性腺功能减退症患病率更高(82.4% vs 55.4%,p=0.040),垂体柄中位直径更大(5.5 mm vs 3.7 mm,p=0.043)。
  • 糖皮质激素抵抗组与无难治组之间未观察到显著差异。
  • 免疫抑制剂(如吗替麦考酚酯)或利妥昔单抗联合治疗可有效实现影像学控制。
  • 糖皮质激素相关不良事件发生于40.9%的患者,最常见为高脂血症和高血糖。

关键数值与推荐

  • 难治性PAH定义为原发糖皮质激素抵抗或减量期间复发(糖皮质激素依赖)。
  • 糖皮质激素依赖型难治组与无难治组的比较:妊娠相关垂体炎5.9% vs 41.7%(p=0.006),血清催乳素中位数30.2 ng/mL vs 17.8 ng/mL(p=0.021),促性腺激素性性腺功能减退症82.4% vs 55.4%(p=0.040),垂体柄中位直径5.5 mm vs 3.7 mm(p=0.043)。
  • 糖皮质激素相关不良事件发生率为40.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucocorticoid (GC) therapy is the cornerstone therapy for primary autoimmune hypophysitis (PAH), yet treatment failure and relapse are common. The concept and optimal management of "refractory" PAH remain undefined. OBJECTIVE: To define the clinical entity of refractory PAH, identify its distinguishing features, develop an exploratory screening model, and propose a structured management pathway based on treatment outcomes. METHODS: A retrospective cohort study of 100 PAH patients was conducted. Refractory PAH was defined as primary GC resistance or recurrence during tapering (GC-dependent). Twenty-two patients met these criteria. Baseline characteristics were compared between groups, and a exploratory screening model developed. RESULTS: Among 100 patients with hypophysitis, 22 (22%) met the criteria for refractory disease, including 19 with GC-dependent and 3 with GC-resistant hypophysitis. Compared with the non-refractory group, GC-dependent refractory hypophysitis was characterized by a lower prevalence of pregnancy-associated hypophysitis (5.9% vs. 41.7%, p=0.006), higher serum prolactin levels (median 30.2 ng/mL vs. 17.8 ng/mL, p=0.021), a higher prevalence of hypogonadotropic hypogonadism (82.4% vs. 55.4%, p=0.040), and a larger median pituitary stalk diameter (5.5 mm vs. 3.7 mm, p=0.043). No significant differences were observed between the GC-resistant group and the non-refractory group. Combination therapy with immunosuppressive agents (e.g., mycophenolate mofetil) or rituximab was effective in achieving radiological control. Glucocorticoid-related adverse events occurred in 40.9% of patients, most commonly hyperlipidemia and hyperglycemia. CONCLUSION: This study defines and characterizes refractory PAH. The distinct clinical characteristics and the proposed structured diagnostic-therapeutic pathway offer a framework for managing this challenging condition.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhai X, Xu Z, Xu T, et al. Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study. J Clin Endocrinol Metab. 2026. PMID: 43017889. doi:10.1210/clinem/dgag434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。